Breaking News
Astellas Provides Update on Fezolinetant New Drug Application in U.S.
Astellas Pharma has announced the US Food and Drug Administration (FDA) notified the company that it is extending the original priority review Prescription Drug User Fee Act (PDUFA) goal date for fezolinetant, an investigational agent for the treatment of moderate to severe vasomotor symptoms (VMS) due to menopause. Astellas was notified on February 17, 2023, that the FDA is extending the PDUFA goal date by three months, to May 22, 2023, to allow more time to complete their review.
“We remain confident in the clinical profile of fezolinetant and the potential benefits it could bring to women experiencing moderate to severe VMS due to menopause, and we will continue to work with the FDA on its review of the NDA for fezolinetant,” said Ahsan Arozullah, M.D., M.P.H., Senior Vice President and Head of Development Therapeutic Areas, Astellas.
The impact of this matter on Astellas’ financial results of the current fiscal year ending March 31, 2023, is expected to be minor.
Companies In This Post
- Insmed Completes Enrollment of Adult Patients in Phase 3 ASPEN Study of Brensocatib in Bronchiectasis Read more
- NEC Establishes Subsidiaries in Europe for Strengthening Global AI Drug Development Business Read more
- Flare Therapeutics Further Strengthens Leadership Team with Key Executive Appointments and Promotions Read more
- Sensorion Appoints Khalil Barrage as Interim Chairman of the Board Read more
- Ablaze Pharmaceuticals Plans Development of Innovative GPC3 Targeted Radiopharmaceutical Therapy for Liver Cancer in Greater China Read more
NEC Establishes Subsidiaries in Europe for Strengthening Global AI Drug Development Business
NEC Corporation and NOI announced that NOI will be realigned as a subsidiary of NEC […]
ProJenX Announces Formation of Scientific Advisory Board for Development of ALS Treatment
ProJenX, a clinical-stage biotechnology company developing novel, brain-penetrant therapies targeting biologically-defined pathways for the treatment […]
AskBio to Present Phase 1b Results Investigating AB-1005 as Treatment for Parkinson’s Disease
Asklepios BioPharmaceutical (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary […]
Hansa Biopharma Announces Positive Reimbursement in Spain for Idefirix as Desensitization Treatment for Patients in Kidney Transplantation
Hansa Biopharma, a pioneer in enzyme technology for rare immunological conditions, has announced that the […]
Lucy Therapeutics Appoints Neuroscience Drug Discovery and Development Expert Christopher J. Winrow, Ph.D., as Chief Scientific Officer
Lucy Therapeutics, a private biotech company developing proprietary mitochondrial-based small molecule therapies and biomarkers for […]
Transcenta’s Osemitamab (TST001) Targeting Claudin18.2 Granted Orphan Drug Designation for Treatment of Pancreatic Cancer
Transcenta, a clinical-stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of […]
OncoVerity Announces Exclusive Worldwide Licensing Rights to Cusatuzumab
OncoVerity, a pioneer in applying advanced multiomic, data driven patient stratification to the development of […]
Insmed Completes Enrollment of Adult Patients in Phase 3 ASPEN Study of Brensocatib in Bronchiectasis
Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients […]
NEC Establishes Subsidiaries in Europe for Strengthening Global AI Drug Development Business
NEC Corporation and NOI announced that NOI will be realigned as a subsidiary of NEC […]
Flare Therapeutics Further Strengthens Leadership Team with Key Executive Appointments and Promotions
Flare Therapeutics, a biotechnology company targeting transcription factors to discover precision medicines for cancer and […]
Sensorion Appoints Khalil Barrage as Interim Chairman of the Board
Sensorion, a pioneering clinical-stage biotechnology company that specializes in gene therapies in the ear, announces […]
Ablaze Pharmaceuticals Plans Development of Innovative GPC3 Targeted Radiopharmaceutical Therapy for Liver Cancer in Greater China
Ablaze Pharmaceuticals, a biotech company that is focused on developing Targeted Radiotherapy (TRT) to benefit […]
Hansa Biopharma Completes Enrollment in Phase 2 Study of Imlifidase in Guillain-Barré Syndrome (GBS)
Hansa Biopharma, a pioneer in enzyme technology for rare immunological conditions, today announced it has […]
ProJenX Announces Formation of Scientific Advisory Board for Development of ALS Treatment
ProJenX, a clinical-stage biotechnology company developing novel, brain-penetrant therapies targeting biologically-defined pathways for the treatment […]